- Home
- BNZI vs MBRX Comparison
BNZI vs MBRX Comparison
Compare BNZI & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BNZI | MBRX |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | United States | United States |
| Employees | 28 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.7M | 12.8M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | BNZI | MBRX |
|---|---|---|
| Price | $1.15 | $2.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $23.00 | ★ $105.50 |
| AVG Volume (30 Days) | ★ 845.9K | 224.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $185.61 | N/A |
| Revenue Next Year | $32.86 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.54 | $0.25 |
| 52 Week High | $4.44 | $7.98 |
Technical Indicators
Market Signals| Indicator | BNZI | MBRX |
|---|---|---|
| Relative Strength Index (RSI) | 45.85 | 32.17 |
| Support Level | $1.07 | $0.37 |
| Resistance Level | $1.40 | $5.22 |
| Average True Range (ATR) | 0.12 | 0.28 |
| MACD | -0.00 | -0.17 |
| Stochastic Oscillator | 30.88 | 5.08 |
Price Performance
Historical ComparisonAbout BNZI Banzai International Inc.
Banzai International Inc is a marketing technology (MarTech) company that produces data-driven marketing and sales solutions for businesses of all sizes. Its mission is to help its customers accomplish their mission by enabling marketing, sales and customer engagement outcomes. The company has two reportable operating segments, Banzai Operating and OpenReel. The company's segments deliver SaaS tools that leverage data, analytics, and AI to provide marketing and sales solutions for business of all size. it derives maximum revenue from Banzai Operating segment. Geographically, it operates in Americas, Europe, Middle East and Africa (EMEA), and Asia Pacific.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.